RADIKAL THERAPEUTICS, INC.

Address

8 SOLVIVA RD
WEST TISBURY, MA, 02575-1626

Information

DUNS: 833130045
# of Employees: 0

Ownership Information

Hubzone Owned: N
Socially and Economically Disadvantaged: N
Woman Owned: Y

Award Charts




Award Listing

  1. Bifunctional K-ATP channel opener and redox catalyst for treatment of hemorrhagic shock

    Amount: $767,994.00

    Radikal Therapeutics RTX is developing a first in class cytoprotective small molecule agent R intended for the acute resuscitation of hemorrhagic shock HS the leading cause of death in trau ...

    SBIRPhase II2017Department of Health and Human Services National Institutes of Health
  2. A pro-resolution lipid mediator for treatment of rheumatoid arthritis

    Amount: $750,000.00

    Radikal Therapeutics is developing the first therapeutic Resolvin molecule intended for the management of rheumatoid arthritis RA Resolvins are endogenous picomolar potent small molecules that acti ...

    SBIRPhase II2016Department of Health and Human Services
  3. Restoration of free radical homeostasis: novel therapy of septic shock

    Amount: $1,248,631.00

    DESCRIPTION provided by applicant Radikal Therapeutics RTX has invented a novel first in class bifunctional nitric oxide NO donor and redox catalyst R to treat septic shoc In rodent and ...

    SBIRPhase II2016Department of Health and Human Services
  4. Treatment of congenital heart disease associated pulmonary hypertension

    Amount: $1,500,000.00

    DESCRIPTION provided by applicant Restoration of the balance of the free radicals nitric oxide NO and superoxide in the pulmonary vasculature may prevent life threatening perioperative pulmonary ...

    SBIRPhase II2015Department of Health and Human Services National Institutes of Health
  5. A Novel Immunotolerizing Therapy for Autoimmune Vitiligo

    Amount: $225,000.00

    DESCRIPTION (provided by applicant): Radikal Therapeutics (RTX) is pioneering a novel therapy to restore immune tolerance and arrest progressive depigmentation in vitiligo. At Loyola University (LUC), ...

    SBIRPhase I2014Department of Health and Human Services
  6. A novel prodrug for K+-ATP channel activation in the glaucomatous eye

    Amount: $225,919.00

    DESCRIPTION (provided by applicant): Radikal Therapeutics (RTX) is developing a revolutionary bifunctional small molecule (R-801) for topical therapy of primary open angle glaucoma (POAG). R-801 is co ...

    SBIRPhase I2014Department of Health and Human Services
  7. Bifunctional potassium-ATP channel opener and redox catalyst for therapy of spina

    Amount: $231,477.00

    DESCRIPTION (provided by applicant): Radikal Therapeutics (RTX) is developing a first-in-class cytoprotective small molecule (R-801) for the prevention of spinal cord injury (SCI) based upon the chem ...

    SBIRPhase I2014Department of Health and Human Services
  8. A potassium-ATP channel opener for prevention of contrast-induced nephropathy

    Amount: $1,527,261.00

    Contrast media (CM) induced nephropathy (CIN) remains prevalent and debilitating, the third most common cause of acute renal failure. Based on more than 80 million (M) CM injections in the USA per ann ...

    SBIRPhase II2014Department of Health and Human Services
  9. A Novel Therapy for Restricted Induction of Tolerance to Treat Diabetes Mellitus

    Amount: $269,865.00

    DESCRIPTION (provided by applicant): We are developing a novel immunomodulatory approach to arrest pancreatic islet injury and restore specific immune tolerance in new-onset Type 1 diabetes mellitus ( ...

    SBIRPhase I2013Department of Health and Human Services
  10. Radiocontrast Nephropathy: Redox Degradation Catalyst and Nitric Oxide Donor

    Amount: $245,133.00

    DESCRIPTION (provided by applicant): We are developing a novel small molecule cytoprotective drug (R-100) for the prevention of contrast- induced nephropathy (CIN) following IV radiocontrast media (CM ...

    SBIRPhase I2013Department of Health and Human Services

Agency Micro-sites

US Flag An Official Website of the United States Government